Drug Profile
PF 5231023
Alternative Names: PF-05231023; PF-5231023Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 05 Mar 2014 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (IV)
- 01 Dec 2013 Pfizer terminates a phase I trial for Type-2 diabetes mellitus in USA (NCT01923389)
- 30 Sep 2013 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA (NCT01673178)